Updates at market open, adds further analyst comment in 4-5 bullets
** Shares in Novo Nordisk NOVOb.CO rise 3% after the Danish drugmaker posted a quarterly operating profit above estimates
** Novo books EBIT of 38.79 billion Danish crowns ($5.91 billion) for Q1, 4% above consensus expectations
** It now expects its sales in 2025 to grow 13%-21%, against the 16%-24% growth it saw in in February
** J.P.Morgan says the outlook cut was largely anticipated by the market
** Any weakness today is a buying opportunity ahead of the potential for improving Wegovy growth, JPM says
** Jefferies analysts say the outlook cut is likely around 1-2 pp more than expected
** Stock down around 29% YTD as of Tuesday's close
($1 = 6.5648 Danish crowns)
(Reporting by Boleslaw Lasocki)
((boleslaw.lasocki@thomsonreuters.com; +48 58 769 66 00;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。